BioCryst Pharmaceuticals Files 8-K: Other Events
Ticker: BCRX · Form: 8-K · Filed: Jun 25, 2025 · CIK: 882796
Sentiment: neutral
Topics: 8-K, other-events
Related Tickers: BCRX
TL;DR
BioCryst filed an 8-K for 'Other Events' on 6/23/25. Details TBD.
AI Summary
On June 23, 2025, BioCryst Pharmaceuticals, Inc. filed an 8-K report. The filing indicates "Other Events" as the primary item of disclosure. No specific details regarding the nature of these events, any associated financial figures, or involved parties were provided in the excerpt.
Why It Matters
This filing signals that BioCryst Pharmaceuticals has reported significant events not covered by other standard 8-K categories, requiring investor attention for potential implications.
Risk Assessment
Risk Level: medium — The filing of an 8-K for 'Other Events' suggests material information has been disclosed, but the lack of specifics in the provided text creates uncertainty about the nature and impact of these events.
Key Players & Entities
- BioCryst Pharmaceuticals, Inc. (company) — Registrant
- June 23, 2025 (date) — Date of earliest event reported
FAQ
What specific 'Other Events' are being reported by BioCryst Pharmaceuticals, Inc. in this 8-K filing?
The provided excerpt of the 8-K filing does not specify the nature of the 'Other Events'.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 23, 2025.
What is the Commission File Number for BioCryst Pharmaceuticals, Inc.?
The Commission File Number for BioCryst Pharmaceuticals, Inc. is 000-23186.
What is the principal executive office address for BioCryst Pharmaceuticals, Inc.?
The principal executive office address is 4505 Emperor Blvd., Suite 200, Durham, North Carolina 27703.
What is the IRS Employer Identification Number (EIN) for BioCryst Pharmaceuticals, Inc.?
The EIN for BioCryst Pharmaceuticals, Inc. is 62-1413174.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 25, 2025 regarding BIOCRYST PHARMACEUTICALS INC (BCRX).